{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:11:43Z","timestamp":1794442303334,"version":"4.9.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cpcardiol.2022.101194","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:00:21Z","timestamp":1649124021000},"page":"101194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Xintian","family":"Shou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101194_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0002","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0003","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-the role of the GLP-1 receptor","author":"Helmstadter","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0004","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.amjmed.2013.02.035","article-title":"Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients","volume":"126","author":"Ji","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"American Diabetes A: Economic Costs of Diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/653789","article-title":"Impact of diabetes on cardiovascular disease: an update","volume":"2013","author":"Matheus","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2017.02.005","article-title":"Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"187","author":"Mentz","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.scitotenv.2013.12.066","article-title":"A bibliometric analysis of research on the risk of engineering nanomaterials during 1999-2012","volume":"473-474","author":"Wang","year":"2014","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0009","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/14712598.2014.920813","article-title":"Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014)","volume":"14","author":"Chen","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0010","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0011","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0012","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Tec"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0013","series-title":"Proceedings of the International Conference on Intelligent User Interfaces","first-page":"98","article-title":"The centrality of pivotal points in the evolution of scientific networks","author":"Chen","year":"2005"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0016","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0017","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0018","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0019","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0021","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0022","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0024","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0025","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0026","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0028","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0029","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","author":"9","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0031","first-page":"369","article-title":"Expert consensus on glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease","volume":"12","author":"Society","year":"2020","journal-title":"Chin J Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0032","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc21-S010","article-title":"American diabetes A: 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0033","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0034","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0035","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0036","first-page":"2396","article-title":"Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review)","volume":"20","author":"Iorga","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0037","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12933-018-0784-y","article-title":"Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II\/III ExSTRESS randomized trial","volume":"17","author":"Besch","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0038","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/dom.13629","article-title":"Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0039","doi-asserted-by":"crossref","first-page":"2S13","DOI":"10.1016\/S1262-3636(17)30068-X","article-title":"GLP-1 receptor agonists and heart failure in diabetes","volume":"43","author":"Scheen","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0041","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/dom.12969","article-title":"Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system","volume":"19","author":"Zimmerman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0042","first-page":"1693","article-title":"Cardioprotection by exenatide: a novel mechanism via improving mitochondrial function involving the GLP-1 receptor\/cAMP\/PKA pathway","volume":"41","author":"Chang","year":"2018","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005146","article-title":"Effects of liraglutide on reperfusion injury in patients with st-segment-elevation myocardial infarction","volume":"9","author":"Chen","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0044","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0045","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0046","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.568632","article-title":"Repurposing antidiabetic drugs for cardiovascular disease","volume":"11","author":"Schubert","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0048","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0049","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","article-title":"An evaluation of liraglutide including its efficacy and safety for the treatment of obesity","volume":"21","author":"Lin","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0051","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0052","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0053","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0054","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: an update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0056","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0057","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1210\/jc.2016-2240","article-title":"GLP-1-RA corrects mitochondrial labile iron accumulation and improves beta-cell function in type 2 Wolfram syndrome","volume":"101","author":"Danielpur","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0058","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17512433.2019.1567328","article-title":"Future perspectives of the pharmacological management of diabetic dyslipidemia","volume":"12","author":"Patti","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0059","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0060","first-page":"18","article-title":"Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes","volume":"10","author":"Charlton","year":"2020","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0061","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40200-015-0215-5","article-title":"Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients","volume":"14","author":"Tabatabaei-Malazy","year":"2015","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0062","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0063","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0166","article-title":"Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways","volume":"50","author":"Erdogdu","year":"2013","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114209","article-title":"A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction","volume":"182","author":"Qian","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0065","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","article-title":"Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy","volume":"143","author":"Dave","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0066","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","article-title":"Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure","volume":"150","author":"Sinha","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0067","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0068","doi-asserted-by":"crossref","first-page":"e3223","DOI":"10.1002\/dmrr.3223","article-title":"Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes","volume":"36","author":"Zhou","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0069","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0070","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/dom.14054","article-title":"Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme","volume":"22","author":"Thethi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0071","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0072","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist","volume":"22","author":"Bucheit","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.cpcardiol.2022.101194_bib0073","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12325-020-01548-y","article-title":"Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy chinese subjects: a double-blind, phase 1, randomized controlled trial","volume":"38","author":"Shi","year":"2021","journal-title":"Adv Ther"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:50:33Z","timestamp":1758941433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0146280622000913"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101194","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101194"}}